Orchestra BioMed Holdings (OBIO) Gross Margin (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Gross Margin of 70.91% for Q1 2026, down 2402.0% year-over-year from 3.08% in Q1 2025, and down 28.97% quarter-over-quarter from 99.84% in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Gross Margin (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Gross Margin for 5 consecutive years, with 70.91% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin fell 2402.0% year-over-year to 70.91%; the TTM figure through Mar 2026 stood at 99.46% (up 687.0% YoY), while the FY2025 annual figure was 99.43%, up 717.0% from the prior year.
- Gross Margin slipped to 70.91% in Q1 2026 per OBIO's latest filing, from 99.84% in the prior quarter.
- Across five years, Gross Margin topped out at 99.84% in Q4 2025 and bottomed at 70.91% in Q1 2026.
- Historically, Gross Margin has averaged 90.98% across 5 years, with a median of 94.34% in 2024.
- Annual changes were most pronounced in 2025 — Gross Margin jumped 2276 bps — and 2026, when it tumbled 2402 bps.
- Orchestra BioMed Holdings' Gross Margin stood at 95.19% in 2022, then fell by 14 bps to 82.06% in 2023, then slipped by 6 bps to 77.08% in 2024, then grew by 30 bps to 99.84% in 2025, then dropped by 29 bps to 70.91% in 2026.
- Business Quant data shows OBIO's Gross Margin at 70.91% in Q1 2026, 99.84% in Q4 2025, and 94.31% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | 71.59% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 71.59% |
| Mar 31, 2026 | 70.91% |
| Dec 31, 2025 | 99.84% |
| Sep 30, 2025 | 94.31% |
| Jun 30, 2025 | 94.50% |
| Mar 31, 2025 | 94.93% |
| Dec 31, 2024 | 77.08% |
| Sep 30, 2024 | 93.11% |
| Jun 30, 2024 | 94.34% |
| Mar 31, 2024 | 94.52% |
| Dec 31, 2023 | 82.06% |
| Sep 30, 2023 | 90.21% |
| Jun 30, 2023 | 94.10% |
| Mar 31, 2023 | 96.22% |
| Dec 31, 2022 | 95.19% |
| Sep 30, 2022 | 95.18% |
| Jun 30, 2022 | 85.04% |
| Mar 31, 2022 | 95.15% |